206 related articles for article (PubMed ID: 33204362)
1. Elevated Levels of Serum Neurofilament Light Chain Associated with Cognitive Impairment in Vascular Dementia.
Ma W; Zhang J; Xu J; Feng D; Wang X; Zhang F
Dis Markers; 2020; 2020():6612871. PubMed ID: 33204362
[TBL] [Abstract][Full Text] [Related]
2. The Relationship between Serum Amyloid A Level and Cognitive Dysfunction in Patients with Vascular Dementia: Preliminary Findings.
Xu M; He XY; Huang P
Biomed Res Int; 2021; 2021():6676144. PubMed ID: 33644229
[TBL] [Abstract][Full Text] [Related]
3. Association of serum neurofilament light chain and glial fibrillary acidic protein levels with cognitive decline in Parkinson's disease.
Mao S; Teng X; Li Z; Zu J; Zhang T; Xu C; Cui G
Brain Res; 2023 Apr; 1805():148271. PubMed ID: 36754139
[TBL] [Abstract][Full Text] [Related]
4. Association of Serum FAM19A5 with Cognitive Impairment in Vascular Dementia.
Li J; Li S; Song Y; Zhou W; Zhu X; Xu S; Ma Y; Zhu C
Dis Markers; 2020; 2020():8895900. PubMed ID: 32831973
[TBL] [Abstract][Full Text] [Related]
5. Decreased Levels of Serum IL-34 Associated with Cognitive Impairment in Vascular Dementia.
Wang Y; Lu W; Ning W; Chen Y; Li L
Biomed Res Int; 2021; 2021():6793860. PubMed ID: 34095310
[TBL] [Abstract][Full Text] [Related]
6. Serum neurofilament is associated with motor function, cognitive decline and subclinical cardiac damage in advanced Parkinson's disease (MARK-PD).
Niemann L; Lezius S; Maceski A; Leppert D; Englisch C; Schwedhelm E; Zeller T; Gerloff C; Kuhle J; Choe CU
Parkinsonism Relat Disord; 2021 Sep; 90():44-48. PubMed ID: 34352610
[TBL] [Abstract][Full Text] [Related]
7. Association between plasma neurofilament light chain levels and cognitive function in patients with Parkinson's disease.
Zhu Y; Yang B; Wang F; Liu B; Li K; Yin K; Yin WF; Zhou C; Tian S; Ren H; Pang A; Yang X
J Neuroimmunol; 2021 Sep; 358():577662. PubMed ID: 34311152
[TBL] [Abstract][Full Text] [Related]
8. Increased Levels of Serum Neuregulin 1 Associated with Cognitive Impairment in Vascular Dementia.
Wang X; Zhang F; Ma W; Feng D; Zhang J; Xu J
Biomed Res Int; 2020; 2020():6683747. PubMed ID: 33274218
[TBL] [Abstract][Full Text] [Related]
9. Serum neurofilament light chain in behavioral variant frontotemporal dementia.
Steinacker P; Anderl-Straub S; Diehl-Schmid J; Semler E; Uttner I; von Arnim CAF; Barthel H; Danek A; Fassbender K; Fliessbach K; Foerstl H; Grimmer T; Huppertz HJ; Jahn H; Kassubek J; Kornhuber J; Landwehrmeyer B; Lauer M; Maler JM; Mayer B; Oeckl P; Prudlo J; Schneider A; Volk AE; Wiltfang J; Schroeter ML; Ludolph AC; Otto M;
Neurology; 2018 Oct; 91(15):e1390-e1401. PubMed ID: 30209235
[TBL] [Abstract][Full Text] [Related]
10. Association Between Longitudinal Plasma Neurofilament Light and Neurodegeneration in Patients With Alzheimer Disease.
Mattsson N; Cullen NC; Andreasson U; Zetterberg H; Blennow K
JAMA Neurol; 2019 Jul; 76(7):791-799. PubMed ID: 31009028
[TBL] [Abstract][Full Text] [Related]
11. Plasma neurofilament light chain is associated with cognitive decline in non-dementia older adults.
He L; Morley JE; Aggarwal G; Nguyen AD; Vellas B; de Souto Barreto P;
Sci Rep; 2021 Jun; 11(1):13394. PubMed ID: 34183688
[TBL] [Abstract][Full Text] [Related]
12. Serum level of YWHAG as a diagnostic marker of cognitive impairment in Parkinson's disease patients.
Peng Y; Zhu L; Bai Q; Wang L; Li Q
Acta Neurol Belg; 2024 Jun; 124(3):879-885. PubMed ID: 38286872
[TBL] [Abstract][Full Text] [Related]
13. Delirium, neurofilament light chain, and progressive cognitive impairment: analysis of a prospective Norwegian population-based cohort.
Krogseth M; Davis D; Jackson TA; Zetterberg H; Watne LO; Lindberg M; Chitalu P; Tsui A; Selbæk G; Wyller TB
Lancet Healthy Longev; 2023 Aug; 4(8):e399-e408. PubMed ID: 37459878
[TBL] [Abstract][Full Text] [Related]
14. Decreased Serum NCAM Levels Associated with Cognitive Impairment in Vascular Dementia.
Zhao J; Lu W; Li J; Liu L; Zhao X
Dis Markers; 2021; 2021():2792884. PubMed ID: 34504627
[TBL] [Abstract][Full Text] [Related]
15. Stage-specific links between plasma neurofilament light and imaging biomarkers of Alzheimer's disease.
Benedet AL; Leuzy A; Pascoal TA; Ashton NJ; Mathotaarachchi S; Savard M; Therriault J; Kang MS; Chamoun M; Schöll M; Zimmer ER; Gauthier S; Labbe A; Zetterberg H; Rosa-Neto P; Blennow K;
Brain; 2020 Dec; 143(12):3793-3804. PubMed ID: 33210117
[TBL] [Abstract][Full Text] [Related]
16. Serum neurofilament light chain in patients with epilepsy and cognitive impairment.
Ueda M; Suzuki M; Hatanaka M; Nakamura T; Hirayama M; Katsuno M
Epileptic Disord; 2023 Apr; 25(2):229-236. PubMed ID: 36939694
[TBL] [Abstract][Full Text] [Related]
17. Association of Plasma Neurofilament Light With Neurodegeneration in Patients With Alzheimer Disease.
Mattsson N; Andreasson U; Zetterberg H; Blennow K;
JAMA Neurol; 2017 May; 74(5):557-566. PubMed ID: 28346578
[TBL] [Abstract][Full Text] [Related]
18. Longitudinal Associations of Blood Phosphorylated Tau181 and Neurofilament Light Chain With Neurodegeneration in Alzheimer Disease.
Moscoso A; Grothe MJ; Ashton NJ; Karikari TK; Lantero Rodríguez J; Snellman A; Suárez-Calvet M; Blennow K; Zetterberg H; Schöll M;
JAMA Neurol; 2021 Apr; 78(4):396-406. PubMed ID: 33427873
[TBL] [Abstract][Full Text] [Related]
19. Plasma tau, neurofilament light chain and amyloid-β levels and risk of dementia; a population-based cohort study.
de Wolf F; Ghanbari M; Licher S; McRae-McKee K; Gras L; Weverling GJ; Wermeling P; Sedaghat S; Ikram MK; Waziry R; Koudstaal W; Klap J; Kostense S; Hofman A; Anderson R; Goudsmit J; Ikram MA
Brain; 2020 Apr; 143(4):1220-1232. PubMed ID: 32206776
[TBL] [Abstract][Full Text] [Related]
20. Plasma neurofilament light chain levels in Alzheimer's disease.
Zhou W; Zhang J; Ye F; Xu G; Su H; Su Y; Zhang X;
Neurosci Lett; 2017 May; 650():60-64. PubMed ID: 28428015
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
